M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring $\alpha_M\beta_2$ Integrin to Tumor Cells

Jindao Wu,1-4* Wen Gao,5* Qiyun Tang,6* Yue Yu,1-3 Wei You,1-3,6 Zhengshan Wu,1-3,6 Ye Fan,1-3,6 Long Zhang,1-3 Chen Wu,1-3 Guoyong Han,1-3 Xueliang Zuo,1-3 Yao Zhang,1-3 Zhiqiang Chen,1-3 Wenzhou Ding,1-3 Xiangcheng Li,1-3 Fengming Lin,7 Hongbing Shen,4,8 Jinhai Tang,6 Yaqin Zhang,9,10 and Xuehao Wang1-4

BACKGROUND AND AIMS: The development and progression of hepatocellular carcinoma (HCC) is dependent on its local microenvironment. Tumor-associated macrophages (TAMs) are deemed a key factor for the tumor microenvironment and attribute to contribute to tumor aggressiveness. However, the detailed mechanism underlying the pro-metastatic effect of TAMs on HCC remains undefined.

APPROACH AND RESULTS: The present study proved that TAMs were enriched in HCC. TAMs were characterized by an M2-polarized phenotype and accelerated the migratory potential of HCC cells in vitro and in vivo. Furthermore, we found that M2-derived exosomes induced TAM-mediated pro-migratory activity. With the use of mass spectrometry, we identified that integrin, $\alpha_M\beta_2$ (CD11b/CD18), was notably specific and efficient in M2 macrophage–derived exosomes (M2 exos). Blocking either CD11b and/or CD18 elicited a significant decrease in M2 exos–mediated HCC cell metastasis. Mechanistically, M2 exosomes mediate an intercellular transfer of the CD11b/CD18, activating the matrix metalloproteinase-9 signaling pathway in recipient HCC cells to support tumor migration.

CONCLUSIONS: Collectively, the exosome-mediated transfer of functional CD11b/CD18 protein from TAMs to tumor cells may have the potency to boost the migratory potential of HCC cells, thus providing insights into the mechanism of tumor metastasis. (HEPATOLOGY 2021;73:1365-1380).

Hepatocellular carcinoma (HCC) not only ranks as the fifth most commonly occurring malignant tumor but also is the second prevalent cause of death across the globe.1 Long-term prognosis for
HCC remains poorly understood, with most patients with HCC dying from extrahepatic metastases, such as lung metastases. Lung metastases often occur by means of hematogenous route with a morbidity of 25%-30% in individuals affected by malignant tumors at autopsy (2); in contrast, the rate observed in patients with HCC is 41.6%-43.6% (3). The calculated mean overall survival (OS) for people suffering from HCC exhibiting metastasis in the lung is approximately 5.9 months, even shorter than that of patients with HCC showing no lung metastasis (approximately 16.2 months) (3).

Accumulating studies on HCC have identified a variety of molecules, such as p53, vascular endothelial growth factor, Ras, and Wnt-1, associated with HCC metastasis (4,5). However, proteins and the precise mechanism associated with lung metastasis of HCC are still unclear.

Recently, a wide array of studies have highlighted the importance regarding the interaction between tumor cells and corresponding microenvironment and the involvement of stromal cells to tumor progression (6,7). The stromal component of tumors consists of endothelial cells, fibroblasts, and tumor-infiltrating inflammatory cells in HCC (8). These cells are known to create a microenvironment modifying the neoplastic properties of tumor cells and are engaged in tumor development and control, and response to treatment options (9,10).

Tumor-associated macrophages (TAMs), a type of inflammatory cells, are believed to foster the pace of cancer initiation and progression (11). For example, a strong association between increased macrophage density and poor survival has been uncovered in HCC (12). Generally, macrophages have the property to be polarized to M1 or M2 macrophages, of which M1-polarized macrophage activation can be stimulated by factors like interferon-γ. M1 polarization is capable of triggering the production of pro-inflammatory and immunostimulatory factors, including IL-12 or tumor necrosis factor α (TNF-α) (10). However, TAMs have been illustrated to more closely resemble the M2-polarized macrophages, which are activated by Th2 cytokines (IL-10, IL-13, and IL-4) (13). Since the link of TAMs to tumors has been unraveled, many recent studies have recognized TAMs as potential exquisite therapeutic targets for cancer. However, the underlying mechanism by which TAMs accelerate metastasis and crosstalk of TAMs with cancer cells awaits extensive elucidation.

Exosomes are denoted as small extracellular vesicles released by most cell types and consist of a lipid bilayer of about 30 nm to 200 nm in diameter. They contain a large variety of biological components (i.e., proteins, lipids, and nucleic acids) that can be functionally transferred from parental cells to
recipient cells. Recent evidence suggests exosomes to be a key communication medium among different kinds of cell types in the tumor microenvironment. However, most of the current studies give attention on tumor cell–derived exosomes, and limited information exists about exosomes from TAM and the effects on tumor cells. Furthermore, the exosomal TAMs are still enigmatic, and the existence of exclusively TAM-secreted exosomes that are essential for tumor progression and metastasis is still elusive.

In the present study, we aimed to delineate the roles of TAM exosomes in the migratory potential of HCC cells as well as the underlying mechanisms. The findings reveal liver TAMs to be primarily a macrophage subpopulation with an M2 phenotype. In specific terms, we highlighted that M2-secreted exosomes (M2 exos) accelerated the migratory potential of HCC cells both in vitro and in vivo. Interestingly, αM integrin (CD11b)/β2 integrin (CD18), commonly referred to as a highly rich protein secreted from M2 exos, was found to be essential in the determination of the migratory potential of HCC cells. One of the underlying mechanisms could be associated with the matrix metalloproteinase-9 (MMP-9), which is required for M2 exos–released CD11b/CD18-mediated invasive potential and metastasis of HCC cells.

Here, we demonstrate that CD11b/CD18, which is an integrin derived from M2 macrophage exosomes, does not affect cancer cell proliferation. However, it expedites the HCC cell invasive potential and metastasis by activating MMP-9. Our findings offer mechanistic insights into macrophage exosomes as mediators in the tumor microenvironment, and the CD11b/CD18 integrin as a modulator of tumor metastasis, thus enhancing to the current knowledge of the tumor-immune interaction.

**Materials and Methods**

**PATIENT ENROLLMENT**

We recruited two independent cohorts of patients with HCC in this study. For the first cohort (cohort 1), we attained 368 pairs of HCC tissue samples and the corresponding adjacent nontumorous tissue samples, along with related clinical information from patients undergoing hepatectomy at the Department of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, between January 2013 and December 2016.

Signed, informed consents were obtained from all participants. Histopathological diagnosis was implemented on the basis of the World Health Organization criteria. According to the classification proposed by Edmondson and Steiner, tumor grade was determined. Assessment of liver function was conducted with the use of the Child-Pugh scoring system. Nonmetastatic HCC samples and HCC metastatic samples (n = 120) in cohort 1 were used for immunohistochemistry (IHC) staining and quantitative real-time PCR (RT-PCR). For the other cohort, we randomly collected patients with HCC undergoing curative resection in 2006 (cohort 2: n = 120). Patients were subjected to postsurgical monitor until April 10, 2016. Postsurgical surveillance was carried out with the use of a previously described method. OS denoted the interval between surgery and death or between surgery and the last observation point. The protocol of this study conformed to the ethical guidelines of the Declaration of Helsinki and was under the approval of the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China).

**STATISTICAL ANALYSIS**

All experiments were repeated at least three times, to confirm the results. The data are presented in the form of mean ± SEM. SPSS 22.0 (SPSS Inc., Chicago, IL) software and Prism 6.0 (GraphPad Software, La Jolla, CA) software were adopted for the Student t test or Wilcoxon matched-pairs test. Categorical data underwent analysis with the use of Fisher’s exact test. Correlation of mRNA expression was determined with the use of Spearman’s analysis. Kaplan-Meier and log-rank analysis were implemented to assess the survival disparity between different subgroups. Differences were considered significant at \( P < 0.05 \).

Other additional experimental procedures can be found in the Supporting Information.

**Results**

**A HIGH LEVEL OF CD206+ TAMS CORRELATE WITH HCC METASTASIS AND PROGNOSIS**

To investigate the role of macrophages in HCC metastasis, we first examined the number of
macrophages in nonmetastatic HCC samples and HCC metastasis samples (cohort 1: n = 120). The level of CD68, a macrophage marker, was assayed in human para-cancer tissues (para-HCC), intracancer tissues (HCC), nonmetastatic HCC tissues (nonmetas HCC), and metastatic HCC tissues (metas HCC). IHC staining of paired tumor (HCC) and peritumor tissues (para-HCC) from patients with HCC showed significantly higher expression of CD68 in HCC tumor tissues than that in peritumor tissues (Fig. 1A,B). To validate the phenotype of CD68+ macrophages in HCC tissues, we further analyzed the expression pattern of CD68, defined as a TAM (M2 macrophage) marker, in human HCC tissues from cohort 1 (n = 120) by means of IHC. We observed a higher density of CD68+ TAMs in HCC tissues versus the para-HCC tissues (Fig. 1C,D), but no difference in the level of CD86+ TAMs (M1 macrophages) between para-HCC tissues and HCC tissues was observed (Supporting Fig. S1A,B). Importantly, we illuminated a higher density of CD206+ TAMs regarding the metas HCC versus the nonmetas HCC (Fig. 1E,F). Furthermore, based on the level of polarization markers, a pro-tumor phenotype was validated in TAMs in human intra-HCC and metas HCC tissues, which was featured by elevated M2 markers (IL-10, Arg1) (Supporting Fig. S1D,E). However, the level of M1 markers (TNF-α, inducible nitric oxide synthase) had no change (Supporting Fig. S1C). Moreover, the infiltration of CD68+ and CD206+ macrophages was correlated with poor clinical outcomes (cohort 2: n = 120) (Fig. 1G,H). Thus, the level of CD206+ macrophages was up-regulated in human HCCs, particularly in patients succumbed to HCC metastasis. Collectively, CD206+ macrophages may have a potential role in HCC progression.

CD206+ M2-POLARIZED MACROPHAGES PROMOTE THE MIGRATION OF HCC CELLS

To unveil the biological function of polarized macrophages, the M1/M2-polarized macrophages were produced in vitro from human macrophages. Previous evidence has documented that differentiated THP-1 monocytes are used extensively to simulate in vitro models of human macrophages. The increased CD68 mRNA and decreased CD14 mRNA, as witnessed by quantitative RT-PCR (Supporting Fig. S2A), illustrate the macrophage-like THP-1 (M0 THP-1) phenotype. In contrast to M1 THP-1 cells, the generated M2-polarized THP-1 macrophages

![Fig. 1] Accumulation of CD206-positive (M2 subtype) TAMs correlates with HCC metastasis and prognosis. (A,C,E) Typical immunohistochemical images of CD68-positive or CD206-positive macrophages in paraneoplastic tissues (para-HCC), intra-HCC tissue (HCC), and metastatic (metas HCC) and nonmetastatic (nonmetas HCC) tumors from patients with HCC in cohort 1 (n = 120; scale bar, 100 μm). (B,D,F) Quantification of CD68-positive or CD206-positive staining in (A), (C), and (E). (G,H) OS of CD68-positive or CD206-positive macrophages in HCC samples (cohort 2: n = 120). **P < 0.01, ***P < 0.001.
were observed to express at a higher level regarding the mannose receptor CD206, along with the diminished levels of TNF-α and CD86 observed (Supporting Fig. S2B,C). The M2-polarized macrophage cytokine profile of higher levels of IL-10 (Supporting Fig. S2D) and lower levels of IL-12 (Supporting Fig. S2E) was also analogous to the cytokine profile of HCC TAMs. We subsequently co-cultured M2 macrophages with HCC cells and illuminated that M2 macrophages significantly accelerated the HepG2 and Huh7 cell migratory potential and invasive potential (Fig. 2A,B), with no clear effect exerted on proliferation (Supporting Fig. S2F-H). M2-polarized macrophages witnessed a similar observation regarding the phenotype profile, while the M2-polarized macrophage conditioned medium (M2 CM) also accelerated the migratory potential and invasive potential of HepG2 cells (Fig. 2C,E) and Huh7 cells (Fig. 2D,F), compared with the M1-polarized macrophage conditioned medium (M1 CM)–treated group or control group. Taken together, these results suggest the potency of M2-polarized macrophages to trigger the migratory potential of HCC cells.

**M2 EXOS PROMOTE HCC CELL MIGRATION**

Emerging evidence suggests the central role of exosomes in cell–cell communication in tumor
metastasis. (22, 23) To explore whether M2 exos have a critical role in promoting the migratory potential of HCC cells, exosomes were isolated from the M2 macrophage culture medium (Fig. 3A–C), followed by the treatment of HCC cells with these isolated exosomes in vitro. As depicted in Fig. 3D,E, PKH26-labeled M2 exos effectively entered recipient HepG2 cells and Huh7 cells stained with or without fluorescein isothiocyanate (FITC)-phalloidin, and significantly boosted the migratory potential and invasive potential capacities of HepG2 cells (Fig. 3F; Supporting Fig. S3A) and Huh7 cells (Fig. 3G; Supporting Fig. S3B), whereas proliferation displayed no clear alterations, as measured by cell cycle analysis (Supporting Fig. S3C,D) and Cell Counting Kit-8 (CCK-8) assay (Supporting Fig. S3I,J). Consistently, incubation of HCC cells with M2 exos–secreted peripheral blood mononuclear cells (PBMC-M2 exos) effectively accelerated the migratory potential and invasive potential of HepG2 cells (Supporting Fig. S3E,G) and Huh7 cells (Supporting Fig. S3F,H) when compared with the PBMC-M1 exo treatment group.

To further study the effect of exosomes on the biological functions of HCC cells in vitro, we adopted a specific exosome secretion inhibitor, GW4869, and added it to the M2 THP-1 macrophage culture medium for assessment of the release of exosomes. A control was set using the same concentration of DMSO. Moreover, western blot analysis revealed that treatment of GW4869 caused a decrease in total protein concentration and expression of CD63 relative to the DMSO treatment (Supporting Fig. S3K,L), suggesting decreased M2 macrophage exosome secretion. Importantly, M2 THP-1 macrophages treated with GW4869 failed to promote the migratory potential and invasive potential of HepG2 cells (Fig. 3H and Supporting Fig. S3M) and Huh7 cells (Fig. 3I and Supporting Fig. S3N). However, GW4869 treatment alone had no impact on the migratory potential and invasive potential of HCC cells (Fig. 3J and Supporting Fig. S3O). These results suggest that M2 exos could be responsible for the effects of M2 macrophages on HCC cells.

To further dissect the effect of M2 exos in vivo, lung metastasis was observed in mice after intravenous administration of HepG2 and Huh7 cells pre-treated with M2 exos with or without GW4869. Histological analysis on lung tissues showed markedly increased incidence of lung metastases in mice inoculated with HepG2 and Huh7 cells treated with M2 exos (Fig. 4A,C). Furthermore, compared with M1 exos–treated cells, lung colonization was found to be increased in mice inoculated with HepG2 and Huh7 cells treated with M2 exos (Supporting Fig. S4A). However, GW4869 treatment significantly reduced the pro-migratory effect of M2 macrophage exosomes on HCC cells (Supporting Fig. S4B). Meanwhile, GW4869 treatment alone does not affect HCC cell lung metastasis when compared with the control group (Supporting Fig. S4B). Moreover, the M2 exos–treatment group had a shorter OS time than the M1 exos–treatment group in the mice (Fig. 4B,D). These findings demonstrate the potential of exosomes derived from M2 macrophages to enhance the aggressiveness of HCC cells, which highlights this mode of communication between macrophages and HCC cells.

**CD11b/CD18 IS ENRICHED IN M2 EXOS**

These data suggest that M2 exos confer certain components to HCC cells, leading to HCC cell migratory potential and metastasis. To identify molecules involved in M2 exos that mediate the HCC cell metastasis, isolated M2 exos (n = 3) and M1 exos (n = 3) were precipitated, followed by protein digestion, isobaric labeling, and quantitative proteomic analysis. Using a nano–liquid chromatography–tandem mass spectrometry assay, we compared the protein expression profiles in M2 exos and M1 exos. The data showed dramatic differential expression of proteins in M2 exos and M1 exos (Supporting Fig. S5A and Supporting Table S3). In particular, a panel of proteins, including fibroleukin (FGL2), fatty acid-binding protein 4 (FABP4), CD37, integrin beta-2 (CD18 or β2 integrin), integrin beta-5 (ITGB5), and integrin alpha-M (CD11b or αM integrin), were significantly up-regulated in M2 exos (Supporting Fig. S5B and Supporting Table S3). Because the family of heterodimeric transmembrane receptors are capable of mediating the cellular interactions with the extracellular matrix (ECM), integrins have a regulatory role in a variety of tumor cell functions, including invasion, proliferation, adhesion, migratory potential, and survival. (24, 25) Here, we focused on CD18 and CD11b, because they
FIG. 3. Exosomes secreted from M2 macrophages promote the migratory and invasive potential of HCC cells in vitro. (A) Transmission electron microscopy image of M2 exos are indicated by red arrows (scale bar, 200 nm). (B) Nanoparticle tracking analysis of M2 exos, confirming the expected size range of 30-200 nm in diameter. (C) Western blot analysis of exosome markers in M2 exos. (D) PKH26-labeled M2 exos (red) incorporation by HepG2 and Huh7 cells detected by confocal microscopy. Nuclei are indicated by 4′,6-diamidino-2-phenylindole (DAPI) staining (scale bar, 50 μm). (E) Uptake of M2 exos by HepG2 and Huh7 cells. Exosomes labeled with PKH26 are stained red, whereas HepG2 and Huh7 cells are stained with FITC-phalloidin, and the DAPI nuclei are stained blue (scale bar, 25 μm). (F,G) HepG2 and Huh7 cell migratory and invasive potential detected by transwell assay and counted after treatment with M1 exos or M2 exos (scale bar, 150 μm). (H,I) M2 macrophages were pretreated with or without GW4869 (10 μM) in M2 macrophage-derived conditioned medium (M2 CM or M2 CM + GW4869), a chemical inhibitor of exosome formation, and the M2 exos were collected. Migratory potential and invasive potential assays of HepG2 and Huh7 cells treated with GW4869, M2 CM, M2 CM + GW4869, or M2 exos. Representative images are shown in the left panel, and migrated cell counts are shown in the right panel (scale bar, 150 μm). The mean ± SEM of three independent experiments are shown. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
are critical molecules in mediating the immune cell extravasation. Functionally, CD18 combines with CD11b to form Mac-1 (CD11b/CD18) on macrophages or other innate cells. Furthermore, western blot assay showed that CD18 and CD11b were the most up-regulated in M2 exos compared with M1 exos. In contrast, ITGB5 was barely detectable in both M2 exos and M1 exos (Fig. 5A,B). Therefore, ITGB5 was not investigated further in this study. In addition, colocalization of CD11b/CD18 and exosomes was detected in HepG2 and Huh7 cells cocultured with M2 exos (Fig. 5C,D), confirming that CD11b/CD18 was transferred from M2 macrophages to HCC cells through exosomes. In addition, the protein levels of CD11b and CD18 were clearly enhanced in HCC cells incubated with M2 exos when compared with the M1 exos–treated group (Fig. 5E,F). Taken together, these results show that CD11b and CD18 can be directly delivered to HCC cells through M2 exos, thus implying a potential role for M2 exos in mediating HCC cell migratory potential.

**CD11b/CD18 ACTS AS A KEY PLAYER IN MEDIATING HCC METASTASIS THROUGH M2 EXOS**

Thereafter, the biological effects of M2 exos–generated CD11b/CD18 on HCC cell metastasis were explored. In consideration of CD11b/CD18’s adhesion function, we first tested the attachment of HCC cells to the endothelium, which is known as a key step for tumor cell metastasis. After M2 exos treatment, HepG2 and Huh7 cells effectively adhered to human umbilical vein endothelial cells. However, the addition of CD11b blocking Ab,
CD18 blocking Ab, or CD11b blocking Ab+CD18 blocking Ab significantly impaired this process (Supporting Fig. S6A–D), suggesting that the uptake of M2 exos–transferred CD11b/CD18 may enhance the attachment of HCC cells to the endothelium. To further test the requirement for M2 exosomal CD11b/CD18 in HCC cell migratory potential, a transwell assay was used. As depicted in Fig. 6A,B, compared with the M2 exos + anti-immunoglobulin G (IgG) blocking Ab–treated group (M2 exos + IgG Ab), the addition of anti-CD11b blocking Ab (CD11b Ab), anti-CD18 blocking Ab (CD18 Ab), or anti-CD11b blocking Ab + anti-CD18 blocking Ab (CD11b/CD18 Ab) to the upper chamber effectively repressed M2 exos–treated HepG2 and Huh7 cells from migrating to the lower chamber. Meanwhile, in the wound-healing assay, the M2 exos + IgG Ab–promoting HCC cell migratory potential was effectively repressed by combination with CD11b Ab, CD18 Ab, or CD11b/CD18 Ab (Supporting Fig. S6E–H). To confirm the specificity of CD11b Ab, CD18 Ab, or CD11b/CD18 Ab, an IgG blocking Ab (IgG Ab) was tested in this study. The addition of this control Ab did not affect the M2 exos–mediated HCC tumor cell migratory potential (Fig. 6 and Supporting Fig. S6; M2 exos versus M2 exos + IgG Ab). For further validation on these data in vivo, male C57BL/6J mice were intravenously injected with M2 exos–treated HCC cells, and then administrated with 30 μg CD11b Ab, CD18 Ab, or CD11b/CD18 Ab twice: 1 hour before and 12 hours after tumor cell injection. The administration of CD11b Ab, CD18 Ab, or CD11b/CD18 Ab effectively repressed the effect of M2 exos on lung metastasis of HepG2 and Huh7 tumors (Fig. 6C,E and Supporting Fig. S6I) and prolonged the survival of mice (Fig. 6D,F). Importantly, compared with M2 exos + CD11b Ab–treated or M2 exos + CD18 Ab–treated groups, the inhibition of both CD11b and CD18 with CD11b Ab + CD18 Ab at the same time (M2 exos + CD11b/CD18 Ab) further reduced HCC migratory potential and invasive
potential in all detections, so there was no significant difference between the M2 exos + CD11b/CD18 Ab–treated group and the control group (Fig. 6 and Supporting Fig. S6). Collectively, these data suggest that CD11b and CD18 are essential for M2 exos to mediate HCC cell metastasis.

**FIG. 6.** M2 exosome–delivered CD11b/CD18 expedites the migratory and invasive potential of HCC cells in vitro and in vivo. (A,B) The migratory and invasive potential of HepG2 and Huh7 cells through transwell assay were detected and counted in the presence of PBS (control), M2 exos, M2 exos + IgG Ab, M2 exos + CD11b Ab, M2 exos + CD18 Ab, or M2 exos + CD11b/CD18 Ab (scale bar, 150 μm). The left panel shows the representative images of three independent experiments, and the right panel shows the combination of those experiments. (C,E) CD11b/CD18–derived M2 exos–mediated HCC cell metastasis in vivo. A total of 1 × 10⁶ HepG2 or Huh7 cells pretreated with control (PBS), M2 exos, M2 exos + IgG Ab, M2 exos + CD11b Ab, M2 exos + CD18 Ab, or M2 exos + CD11b/CD18 Ab was injected into mice through their tail veins (n = 10–11 per group). The mice were treated with 30 μg anti-IgG Ab, anti-CD18 Ab, anti-CD11b Ab, or anti-CD11b Ab+anti-CD18 Ab twice: 1 hour before and 12 hours after tail vein injection. After 3 weeks, the mice were killed and the lungs were examined for metastatic lesions, and the number of visible metastatic nodules was counted. Representative images of hematoxylin and eosin staining of metastatic nodules in lungs from different animal groups (left panel: upper scale bar, 1,500 μm; lower scale bar, 150 μm). The average number of visible lung metastases quantified in each group is indicated (right panel). Black arrows show the metastasis nodules in the lung. (D,F) Long-term survival of the mice. The results were combined from two reproducible experiments (n = 6 for each group). All values are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; #P < 0.05, M2 exos + CD11b Ab or M2 exos + CD18 Ab versus control; not significant, M2 exos + CD11b/CD18 Ab versus control.
MMP-9 INDUCTION BY CD11b/CD18-BEARING M2 EXOS IS INVOLVED IN LUNG METASTASIS OF HCC TUMORS

We next proceeded to unveil the modulators of M2 exo–derived CD11b/CD18-driven pro-migratory properties of HCC cells. Existing evidence has suggested the ability of MMPs to degrade the ECM during the early stages of many malignant tumors, which plays an important role in the invasive potential and metastasis of tumors.(28) Activation of Mac-1 existing on the surface of neutrophils has the potency to induce their MMP-9 release, showing a probability to cause the mobilization of bone marrow–derived stem cells.(29) To investigate the mechanism by which M2 exos–derived CD11b/CD18 regulates the migratory potential and invasive potential of HCC cells, we measured MMP-9 expression and release in HepG2 and Huh7 cells treated with the various indicated treatments using quantitative RT-PCR, western blot, and enzyme-linked immunosorbent assays, respectively. The results revealed that M2 exos–treated HCC cells had markedly increased mRNA and protein levels of MMP-9 compared with M1 exos–treated HCC cells (Supporting Fig. S7A-D). Meanwhile, M2 exos–treated HCC cells induced more active MMP-9 release compared with M1 exos–treated HCC cells (Supporting Fig. S7E,F). Furthermore, M2 exos–induced expression of MMP-9 was effectively repressed by the addition of CD11b Ab, CD18 Ab, or CD11b/CD18 Ab in treated HCC cells (Fig. 7A-D). Moreover, when CD11b Ab, CD18 Ab, or CD11b/CD18 Ab was added to M2 exos–treated HCC cells, the enhanced effect of M2 exos–induced MMP-9 secretion in HCC cells was significantly repressed (Fig. 7E,F).

To further validate the role of MMP-9 in mediating the enhanced migratory potential of M2 exos–derived CD11b/CD18 in treated HCC cells, a selective chemical MMP inhibitor CP471474, known to potently block MMP-9 activity,(30) was

---

**FIG. 7.** Exosomal transfer of CD11b/CD18 from M2 macrophages expedites the migratory potential of HCC cells through MMP-9 activation. Quantitative RT-PCR (A,B) and immunoblotting (C,D) assays of MMP-9 mRNA and protein levels in HepG2 (A,C) and Huh7 (B,D) cells cultured with M2 exos, M2 exos + IgG Ab, M2 exos + CD11b Ab, M2 exos + CD18 Ab, M2 exos + CD11b/CD18 Ab, or PBS treatment (control). (E,F) Enzyme-linked immunosorbent assay analysis of MMP-9 activation in HepG2 (E) and Huh7 (F) cells treated as in (A). The Student t-test was used to analyze the differences. All values are presented as the mean ± SEM. *P < 0.05, **P < 0.01; #P < 0.05, M2 exos + CD11b Ab or M2 exos + CD18 Ab versus control; not significant, M2 exos + CD11b/CD18 Ab versus control. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
used in the present study. At 10 nM for 24 hours, the administration of CP471474 did not significantly reduce the survival of HepG2 and Huh7 cells in a CCK-8 assay (Supporting Fig. S8A,B). Importantly, the inhibitor induced a significant reduction of MMP-9 protein level in treated HepG2 and Huh7 cells (Supporting Fig. S8C,D). Furthermore, compared with M2 exos–treated cells, the co-culture of HepG2 and Huh7 cells with M2 exos and MMP-9i (CP471474, 10 nM) led to a significant reduction in the HCC cell migratory potential in the transwell assay (Fig. 8A) and wound healing assay (Fig. 8B,C). In agreement with these results, we illuminated that the administration of M2 exos + MMP-9i to HCC cells effectively repressed the effect of M2 exos on lung metastasis of HepG2 and Huh7 tumors compared with the M2 exos–treated group (Fig. 8D). Moreover, we further demonstrated that there was no significant difference in the metastatic effects between the M2 exos + CD11b/CD18 Ab–treated group and the M2 exos + CD11b/CD18 Ab+MMP-9i–treated HCC cells (Supporting Fig. S8E,F).

Collectively, these results suggest that the correlation between M2 exos–derived CD11b/CD18 and MMP-9 is attributed to MMP-9 activation for subsequent steps in the metastatic process. That is, M2 exos–derived CD11b/CD18 could be involved in the initial metastatic steps (migratory potential, invasion, and MMP-9 activation), whereas active MMP-9 was found to be involved in subsequent metastatic steps (invasion and distal colonization). However, it is unclear how exosomal CD11b/CD18 modulates the MMP-9 secretion of HCC cells. Therefore, we aimed to unravel this question in our future work.

**FIG. 8.** MMP-9 blockade in HCC cells inhibits the M2 exo–induced HCC cell migratory potential. (A) Cell migratory potential was determined using transwell assay in HepG2 and Huh7 cells treated with M2 exos, M2 exos in combination with CP471474, a chemical inhibitor of MMP-9 (MMP-9i, 10 nM), or MMP-9i for 24 hours. The number of migrated cells was counted. (B,C) HepG2 and Huh7 cells were treated as in (A) or (B), and then cell migratory potential was tested using wound-healing assays. Representative images (left panel) and the quantified migrating percentage (right panel) are shown (scale bar, 150 μm). (D) HepG2 and Huh7 cells were co-cultured with PBS (control), MMP-9i, M2 exos, or M2 exos + MMP-9i, collected, and injected into caudal veins of 6-week to 8-week-old male C57BL/6 mice (eight mice for each group). The number of mice with pulmonary metastasis was calculated in each group, as presented in the tables. Mice with pulmonary metastasis were marked “1”, and mice without pulmonary metastasis were marked “0”. The Student t test was used to analyze the differences. All values are presented as the mean ± SEM. *P < 0.05, **P < 0.01.
Discussion

Metastasis attributes to over 90% of cancer-related mortalities. These secondary growths originate from a multistep process in which cancer cells of primary tumors separate themselves with neighboring cells. The cancer cells invade the basement membrane, which entails cellular adhesion loss, potentiated cancer cell migratory potential, and intravasation to the blood or lymph vessels. Furthermore, cancer cells transport with the use of the circulatory system and eventually travel to distant positions.

Genetic and epigenetic changes of tumor cells are the primary drivers in invasive potential and metastasis. In addition, a number of studies have also suggested the strong correlation of cancer cell exposure to paracrine signals and tumor metastasis. In terms of microenvironment, various kinds of stromal cells have been forced to be recruited and localized to malignancies, which enhances the aggressiveness of primary cancer and facilitates metastasis to distant sites. HCC invasive and metastatic properties are extensively reported to be tightly linked to their microenvironment. To attain a better understanding on the role of stromal cells in hepatic tumorigenesis as well as metastasis, we intended to dissect the effects along with the molecular mechanisms behind TAMs in the progression of HCC metastatic activities.

TAMs are associated with myeloid-derived suppressor cells and are the key prototypic components of inflammation that drive neoplastic progression. It is known that solid tumors are generally infiltrated by macrophages. There have been a number of studies proposing the involvement of macrophage surface markers and various classes of macrophages. CD68 is revealed to be expressed in all macrophages and thus works as a pan-macrophage biomarker. Unfortunately, CD68 does not have the ability to effectively distinguish M1 subtype macrophages from M2 subtype macrophages. M1 macrophages have been unveiled to express high levels of CD86, CD11c and TNF-α, whereas M2 macrophages express relatively high levels of CD163, IL-10, and CD206. Interestingly, in HCC, M1 macrophages have an increased CD86 level relative to CD11c and TNF-α, whereas M2 macrophages have an increased CD206 level relative to CD163 and IL-10. Therefore, in the present study, we first investigated the distribution and composition of macrophage subpopulations in para-HCC tissues, intra-HCC tissues, nonmetastatic HCC tissues, and metastatic HCC tissues. Using CD206 and CD86 as subpopulation markers for TAMs, we revealed that most CD68+ TAMs were CD206+ cells in the intra-HCC tissues compared with the para-HCC tissues. However, no significant difference was observed in the percentage of CD86+ TAMs between intra-HCC and para-HCC tissues according to the IHC assay. Moreover, CD68+ TAMs comprised a higher percentage of CD206+ in the metastatic HCC tissues than nonmetastatic HCC tissues. Most importantly, a high level of CD206+ TAMs had a marked correlation with aggressive tumor phenotypes, including tumor size, vascular invasion, the status of metastasis, and advanced tumor-node-metastasis stage (Supporting Table S1), and was associated with poor OS (Fig. 1H). Although TAMs have been suggested to enhance the invasiveness and tumorigenicity of cancer cells by means of producing a multitude of chemokines, cytokines, and growth factors, the molecular mechanisms of their interaction with cancer cells is poorly understood.

Increasing evidence has revealed the stromal cell exosomes as mediators of cell–cell communication within the tumor microenvironment. For instance, inconsistent with our study, Lan et al. suggested that M2 exos accelerated the cell migratory potential and invasive potential in colon cancer. Meanwhile, exosomes denote a key factor in the communication between cancer cells and macrophages in HCC. Exosomes derived from HCC cells have been declared to elicit polarization of tumor-promoting M2 macrophages, which indicates a role that exosomes play in the crosstalk between macrophages and HCC cells. Consistently, our study further demonstrates that M2 exos enhance the cancer cell motility, invasive potential capability, and metastasis, but have no effect on cancer cell proliferation.

Exosomes possess the ability to transfer different kinds of proteins, RNA, and DNA that have intriguing and elaborate roles in cancer progression. The protein significantly enriched in M2 exos was CD11b/CD18 in the present study (Fig. 5). Consistently, the integrin, CD11b/CD18, is defined as a receptor existing on the surface of neutrophils and monocytes/macrophages, not only supporting the adhesion of these cells to ECM proteins and counter-receptors on various cells, but also regulating many responses, including migratory potential, aggregation, phagocytosis, and degranulation.
Moreover, integrin-derived tumor exosomes were shown to promote the metastasis of disseminating cancer cells.\(^{(17)}\) Similarly, our study shows that the CD11b/CD18-derived M2 exos are key in mediating HCC tumor cell metastasis. Moreover, the present study delineated that the M2 exos–mediated pro-migratory ability was dependent on CD11b/CD18, which was confirmed both \textit{in vivo} and \textit{in vitro} by the blockade of either CD11b and/or CD18 in M2 exos–treated HCC cells. Furthermore, the metastatic effects of M2 exos–treated HCC cells were significantly reduced but not completely abolished, by inhibition of CD11b or CD18. That is, there was still a significant difference between M2 exos + CD11b Ab or M2exos + CD18 Ab and the control group. On the other hand, inhibition of both CD11b and CD18 at the same time further reduced M2 exos–treated HCC cell migratory potential and invasive potential (Fig. 6 and Supporting Fig. S6A-I). That is, there was no significant difference between M2 exos + CD11b/CD18 Ab and the control group. Additionally, there are a number of exosome studies showing that micro RNAs in exosomes play an important role in mediating exosome function. To exclude the function of exosomal miRNAs in up-regulating the CD11b/CD18 expression in M2 exos–treated HCC cells, M2 exos were treated with or without RNase A. The results demonstrate that RNase A treatment did not affect M2 exos function in HCC cell invasive potential and migratory potential (Supporting Fig. S6f-M). Hence, our study identified a critical role that macrophage exosome–derived CD11b/CD18 played in controlling the crosstalk between TAMs and HCC cells and promoting metastasis.

Nonetheless, exosomes have reported possessing an important role in the context of cell signal transduction. However, the role of transferable CD11b/CD18 from M2 macrophage exosomes in driving the HCC migratory signaling pathway is elusive. Accordingly, two independent reports demonstrated that the migratory potential of invasive cells was dependent on MMPs anchored on the cell surface through integrins,\(^{(46)}\) whereas the expression of MMP-9 was induced as a result of CD11b/CD18 integrin ligation in polymorphonuclear neutrophils.\(^{(47)}\) In the present study, we showed that the M2 exos–derived CD11b/CD18-driven pro-migratory potential of HCC cells significantly induced the expression and release of MMP-9 from HCC cells. It appears that M2 exos–derived CD11b/CD18 functions as a metastasis enhancer through up-regulation and activation of MMP-9. However, when MMP-9 expression was inhibited, the metastatic effects of M2 exos–treated HCC cells were significantly reduced (Fig. 8). Notably, a previous study has shown that increased integrin content in breast cancer cells was correlated with metastasis, and its mechanism indicated that \(\alpha V\beta 3\) (an integrin) cooperates with MMP-9 in an activation-dependent pathway to promote the migratory potential of metastatic breast cancer.\(^{(48)}\) The present study shows that M2 exos are responsible for the increase in an integrin (\(\alpha M\beta 2\)) in HCC cells and consequent metastasis.

Collectively, our results demonstrate that CD11b/CD18 derived from M2 exos in HCC stroma has the potential to induce cancer cell–invasive potential and metastasis by means of up-regulating MMP-9 expression, whereas the blockage of CD11b/CD18 expression in M2 exos–treated HCC cells abolishes these effects. All of these findings support CD11b/CD18 in being a key biomarker in activated TAMs for HCC diagnosis. Notably, several studies have investigated the use of cancer therapies targeting MMP in clinical trials with little success. A valuable contribution of this study is the identification of the important role of CD11b/CD18 in HCC metastasis, providing an alternative target that may prove to be more useful in the clinic where MMP-targeting agents have failed. Thus, we propose that the interruption of the CD11b/CD18-MMP-9 pathway could be a useful therapeutic approach for controlling HCC metastasis. However, further investigation is warranted. It will be essential to further compare the CD11b knockout or mutant mice with wild-type mice in tumor metastasis in our future work. Additionally, the function of FGL2, FABP4, and CD37 highly expressed in the M2 exos will be warranted in our future investigation.

\textbf{Author Contributions:} J.W.: Conceptualization; Writing-review & editing. W.G.: Validation; Investigation. Q.T.: Supervision; Funding acquisition. Y.Y.: Project administration. W.Y. Methodology. Z.W.: Methodology. Y.F.: Methodology. L.Z.: Methodology. C.W.: Methodology. W.G.: Software. X.Z.: Visualization. Y.Z.: Validation. Z.C.: Validation. W.D.: Resources. X.L.: Funding acquisition. F.L.: Resources. H.S.: Funding acquisition; Supervision. J.T.: Supervision; Funding acquisition. Y.Z.: Formal Analysis; Data curation; Writing-original draft. X.W.: Supervision; Funding acquisition.
REFERENCES

1) El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2) Davidson RS, Nwogu CE, Brentjens MJ, Anderson TM. The surgical management of pulmonary metastasis: current concepts. Surg Oncol 2001;10:35-42.
3) Zhang SM, Zeng ZC, Tang ZY, Sun J, Cheng JM, Liu R, et al. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol Int 2008;2:237-243.
4) Wang YH, Dong YY, Wang WM, Xie XY, Wang ZM, Chen RX, et al. Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kappaB pathways induced by paracrine cytokines. J Exp Clin Cancer Res 2013;32:51.
5) Steinswøy SN, Zanudo JG, Ding W, Routburee CT, Feijt DJ, Loughran TP Jr., et al. Network modeling of TGFbeta signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation. Cancer Res 2014;74:5963-5977.
6) Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-147.
7) Hu M, Polvak Y. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008;18:27-34.
8) de Visser KE, Eichent A, Cousseins LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
9) Cousseins LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-291.
10) Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
11) Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012;42:1-7.
12) Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009;40:381-389.
13) Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. HEPATOLOGY 2014;59:2034-2042.
14) Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569-579.
15) Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011;2:180.
16) Sagar G, Sah RP, Javed N, Dutta SK, Smny KC, Lau JS, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut 2016;65:1165-1174.
17) Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesitote A, et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015;527:329-335.
18) Wittkeind C. Pitfalls in the classification of liver tumors. Pathologie 2006;27:289-293.
19) Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. HEPATOLOGY 2012;56:2242-2254.
20) Hallmann R, Zhang X, Di Russo J, Li L, Song J, Hannocks MJ, et al. The regulation of immune cell trafficking by the extracellular matrix. Curr Opin Cell Biol 2015;36:54-61.
21) Ye YC, Zhao J, Lu Y, Gao CC, Yang Y, Liang SQ, et al. Notch signaling via Wnt regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res 2019;79:4160-4172.
22) Fang JH, Zhang ZJ, Shang LR, Luo YW, Lin YF, Yuan Y, et al. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. HEPATOLOGY 2018;68:1459-1475.
23) Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016;30:836-848.
24) Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-1033.
25) Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
26) Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990;75:1037-1050.
27) Tan SM. The leukocyte beta2 (CD18) integrins: the structure, functional regulation and signalling properties. Biosci Rep 2012;32:241-269.
28) Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007;48:323-334.
29) Inoue T, Taguchi I, Abe S, Toyota S, Nakajima K, Sakuma M, et al. Activation of matrix metalloproteinase-9 is associated with mobilization of bone marrow-derived cells after coronary stent implantation. Int J Cardiol 2011;152:332-336.
30) Rohde DE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-3070.
31) Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-256.
32) Jia YL, Shi L, Zhou JN, Fu CJ, Chen L, Yuan HF, et al. Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. HEPATOLOGY 2011;54:1808-1818.
33) Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-252.
34) Liu LZ, Zhang Z, Zheng BH, Shi Y, Duan M, Ma LJ, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. HEPATOLOGY 2019;69:143-159.
35) Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006;97:439-447.
36) Heiskala M, Leidenius M, Joensuu K, Heikkinen P. High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows Arch 2019;474:3-12.
37) Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulated macrophages. Cancer Res 2009;69:9395-9403.
38) Falini B, Flenghi L, Pilieri S, Gambacorta M, Bigerna B, Durkop H, et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 1993;142:1359-1372.
39) Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-896.
40) Tan HY, Wang N, Man K, Tsao SW, Che CM, Fung Y. Autophagy-induced RbP/p52 activation mediates tumour-associated macrophage polarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death Dis 2015;6:e1942.
41) Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tesitore A, et al. The inflammatory microenvironment in
hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013;2013:187204.

42) Zhang L., Zhang S., Yao J., Lowery FJ., Zhang Q., Huang WC., et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 2015;527:100-104.

43) Lan J., Sun L., Xu F., Liu L., Hu F., Song D., et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res 2019;79:146-158.

44) Li X., Lei Y., Wu M., Li N. Regulation of macrophage activation and polarization by HCC-derived exosomal IncRNA TUC339. Int J Mol Sci 2018;19:2958.

45) Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010;107:8363-8368.

46) Bjorklund M., Heikkila P., Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem 2004;279:29589-29597.

47) Wize J., Sopata I., Smerdel A., Maslinski S. Ligation of selectin L and integrin CD11b/CD18 (Mac-1) induces release of gelatinase B (MMP-9) from human neutrophils. Inflamm Res 1998;47:325-327.

48) Rolli M., Fransvea E., Pitil J., Saven A., Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:9482-9487.

Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31432/supplinfo.